ArticleJournal of applied microbiology2022
Low molecular weight chitooligosaccharide inhibits infection of SARS-CoV-2 in vitro.
Article in Journal of applied microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 18 citations in OpenAlex.
- Prospects of Innovative Therapeutics in Combating the COVID-19 Pandemic.Molecular biotechnology · 2025Review
- In Vivo Evidence on the Emerging Potential of Non-Digestible Oligosaccharides as Therapeutic Agents in Bacterial and Viral Infections.Nutrients · 2025Review
- Chitooligosaccharides suppress airway inflammation, fibrosis, and mucus hypersecretion in a house dust mite-induced allergy model.Frontiers in allergy · 2025Article
- How Do Cyclodextrins and Dextrans Affect the Gut Microbiome? Review of Prebiotic Activity.Molecules (Basel, Switzerland) · 2024Review
- Applications of Chitosan in Prevention and Treatment Strategies of Infectious Diseases.Pharmaceutics · 2024Review
- Chitooligosaccharide and Its Derivatives: Potential Candidates as Food Additives and Bioactive Components.Foods (Basel, Switzerland) · 2023Review
- Chitinase-Assisted Bioconversion of Chitinous Waste for Development of Value-Added Chito-Oligosaccharides Products.Biology · 2023Review
- Potential Medical Applications of Chitooligosaccharides.Polymers · 2022Review
- Low molecular weight chitooligosaccharide inhibits infection of SARS-CoV-2 in vitro.Journal of applied microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
aimsThe discovery of antiviral substances to respond to COVID-19 is a global issue, including the field of drug development based on natural materials. Here, we showed that chitosan-based substances have natural antiviral properties against SARS-CoV-2 in vitro. METHODS AND
resultsThe molecular weight of chitosan-based substances was measured by the gel permeation chromatography analysis. In MTT assay, the chitosan-based substances have low cytotoxicity to Vero cells. The antiviral effect of these substances was confirmed by quantitative viral RNA targeting the RdRp and E genes and plaque assay. Among the substances tested, low molecular weight chitooligosaccharide decreased the fluorescence intensity of SARS-CoV-2 nucleocapsid protein of the virus-infected cells in a dose-dependent manner.
conclusionsIn conclusion, the chitooligosaccharide, a candidate for natural treatment, has antiviral effects against the SARS-CoV-2 virus in vitro. SIGNIFICANCE AND IMPACT OF STUDY: In this study, it was suggested for the first time that chitosan-based substances such as chitooligosaccharide can have an antiviral effect on SARS-CoV-2 in vitro.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.